For almost 20 years, we have been developing new diagnostics at our R&D labs in North Wales, for use in hospitals and by medical researchers . This year, we launched our 10 minute rapid test for the detection of a sepsis biomarker called soluble Toll-like receptor 2 (sTLR2) at the BIO2025 convention in Boston, Massachusetts.
sTLR2 is detectable early on in sepsis, and acts as a decoy receptor in the blood stream to downregulate inflammation associated with sepsis.
Dr Rees, founder and director of J R Biomedical said, “We have worked closely with Cardiff University to develop a rapid test for soluble Toll-like receptor 2 (sTLR2), a new biomarker for sepsis and inflammation, which has the potential to provide further information for clinicians, in addition to traditional biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT)."
"During the R&D phase of the rapid test we also developed a portfolio of proprietary antibodies that react specifically with sTLR2, which can be used in a wide range of immunoassay systems and detection methods, either commercially or for research purposes.”
The sTLR2 RAPID test is manufactured at our North Wales labs and is strictly for professional laboratory use in hospitals. Each kit contains 10 individual test cassettes, requiring a 20µL whole blood, plasma or serum sample, and gives a semi-quantitative result in 10 minutes without the need for any additional equipment.
The global sepsis diagnostics market, currently valued at $840 million, is projected to reach $2 billion by 2032. Commercial opportunities for global licensing of the antibody portfolio and diagnostics are available.
For further information please see imiwn.com